Document is current
Any future updates will be listed below
-
Authors
Jinno, Sadao https://orcid.org/0000-0003-3021-183X
Onishi, Akira https://orcid.org/0000-0002-3120-1273
Dubreuil, Maureen https://orcid.org/0000-0002-6253-1515
Akashi, Kengo https://orcid.org/0000-0002-5289-139X
Hashimoto, Motomu https://orcid.org/0000-0002-9241-060X
Yamamoto, Wataru https://orcid.org/0000-0002-0810-4221
Murata, Koichi https://orcid.org/0000-0002-7896-3937
Takeuchi, Tohru https://orcid.org/0000-0002-0065-929X
Kotani, Takuya https://orcid.org/0000-0003-2190-0780
Maeda, Yuichi https://orcid.org/0000-0002-6831-8205
Ebina, Kosuke https://orcid.org/0000-0002-2426-1024
Son, Yonsu https://orcid.org/0000-0001-7244-7715
Amuro, Hideki https://orcid.org/0000-0002-7299-2884
Hara, Ryota https://orcid.org/0000-0001-8000-3196
Katayama, Masaki https://orcid.org/0000-0002-0773-7238
Saegusa, Jun https://orcid.org/0000-0001-7606-3743
Morinobu, Akio https://orcid.org/0000-0002-4672-638X
-
Funding
Funding for this research was provided by:
AbbVie
Asahi Kasei Pharma Corporation
Chugai Pharmaceutical
Eisai
Janssen Pharmaceuticals
Ono Pharmaceutical
Sanofi
Center for Information Technology
- License Information
-
More Information
Article History
Received: 1 June 2020
Accepted: 21 July 2020
First Online: 29 July 2020
Compliance with ethical standards
:
: Sadao Jinno has received speaking fees from AbbVie G.K., Asahi Kasei Pharma., Bristol-Myers Squibb., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., Janssen Pharmaceutical K.K., and Mitsubishi Tanabe Pharma, and Ono Pharmaceutical Co.. Akira Onishi reports grants from Advantest, personal fees from Asahi Kasei Pharma, personal fees from Chugai Pharmaceutical Co., Ltd., personal fees from Eli Lilly Japan K.K, personal fees from Ono Pharmaceutical Co., personal fees from Mitsubishi Tanabe Pharma, personal fees from Takeda Pharmaceutical Company Limited, personal fees from Daiichi Sankyo Co. Ltd. Motomu Hashimoto and Koichi Murata belong to the department that is financially supported by five pharmaceutical companies (Tanabe-Mitsubishi, Chugai, Ayumi, UCB-Japan and Asahi-Kasei), Nagahama city and Toyooka city. Motomu Hashimoto has received speaking fees from Mitsubishi Tanabe Pharma and Bristol-Myers Squibb; and has received research grants from Eli Lily and Eisai. Koichi Murata has received a speaking fee and/or consulting fee from Eisai Co., Ltd.. Tohru Takeuchi has received grants from Chugai Pharmaceutical Co. Ltd, personal fees from Astellas Pharma Inc, Chugai Pharmaceutical Co. Ltd, Mitsubishi Tanabe Pharma Corporation, AbbVie GK, Bristol Myers Squibb, AYUMI Pharmaceutical Co., Daiichi Sankyo Co. Ltd, Eisai Co. Ltd, Takeda Pharmaceutical Co. Ltd, and Asahi Kasei Corporation. Yuichi Maeda received a research grant and/or speaker fee from Eli Lilly Japan K.K., Chugai Pharmaceutical Co. Ltd., Pfizer Inc., Bristol Myers Squibb, and Mitsubishi Tanabe Pharma Corporation. Kosuke Ebina has received speaking fees from AbbVie G.K., Asahi Kasei Pharma., Astellas Pharma Inc., AYUMI Pharmaceutical Co., Bristol Myers Squibb, Chugai Pharmaceutical Co. Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Corporation, and Ono Pharmaceutical Co., Sanofi K.K., Taisho, and UCB Japan; and has received research grants from AbbVie G.K., Asahi Kasei Pharma., Astellas Pharma Inc., Chugai Pharmaceutical Co. Ltd., Eisai Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Ono Pharmaceutical Co., Taisho, and UCB Japan. Yonsu Son has received speaking fees from Actelion, Bristol-Myers Squibb., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., and Mitsubishi Tanabe Pharma, and Sanofi K.K.. Hideki Amuro has received speaking fees from Asahi Kasei Pharma Corporation, Mitsubishi Tanabe Pharma Corporation, Astellas Pharma Inc., and Novartis Pharma KK. Ryota Hara has received speaking fees from AbbVie G.K.. Jun Saegusa has received speaking fees from AbbVie G.K., Asahi Kasei Pharma., Eli Lilly Japan K.K. and Janssen Pharmaceutical K.K.. Akio Morinobu has received speaking fees from Eli Lilly Japan K.K., Ono Pharmaceutical Co., Pfizer Inc., and UCB Japan.; and has received research grants from AbbVie G.K., Asahi Kasei Pharma., Chugai Pharmaceutical Co. Ltd., and Ono Pharmaceutical Co.. All other authors have declared no conflict of interests.
: This observational study was conducted as per the Declaration of Helsinki and was approved by the ethics committees of all seven institutes.
